CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 32,065 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Follow-Up Questions
Qui est le CEO de CSL Ltd ?
Mr. Paul Mckenzie est le Chief Executive Officer de CSL Ltd, il a rejoint l'entreprise depuis 2019.
Quelle est la performance du prix de l'action CMXHF ?
Le prix actuel de CMXHF est de $135, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de CSL Ltd ?
CSL Ltd appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de CSL Ltd ?
La capitalisation boursière actuelle de CSL Ltd est de $65.4B
Est-ce que CSL Ltd est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 19 analystes ont établi des notations d'analystes pour CSL Ltd, y compris 5 achat fort, 10 achat, 6 maintien, 0 vente et 5 vente forte
